Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(1.70)
# 3,103
Out of 4,732 analysts
38
Total ratings
40.54%
Success rate
-2.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterates: Overweight | n/a | $72.51 | - | 6 | Jun 20, 2024 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $1.87 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint Pharmaceuticals | Reiterates: Overweight | n/a | $7.48 | - | 6 | Jun 20, 2024 | |
| BLTE Belite Bio | Reiterates: Overweight | n/a | $56.21 | - | 3 | Jun 20, 2024 | |
| ALLK Allakos | Reiterates: Neutral | n/a | $0.86 | - | 4 | Jun 20, 2024 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $1.11 | - | 3 | May 15, 2024 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $0.71 | +181.69% | 2 | Aug 31, 2023 | |
| CKPT Checkpoint Therapeutics | Maintains: Overweight | $19 → $14 | $3.18 | +340.25% | 4 | Aug 15, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $4.37 | +655.15% | 2 | Jul 27, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Overweight | $5 → $4.5 | $2.37 | +89.87% | 2 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $100 | $1.72 | +5,730.90% | 2 | May 17, 2022 |
Insmed
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $72.51
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.87
Upside: -
EyePoint Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.48
Upside: -
Belite Bio
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $56.21
Upside: -
Allakos
Jun 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.86
Upside: -
Precigen
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.11
Upside: -
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $0.71
Upside: +181.69%
Checkpoint Therapeutics
Aug 15, 2023
Maintains: Overweight
Price Target: $19 → $14
Current: $3.18
Upside: +340.25%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $4.37
Upside: +655.15%
ProQR Therapeutics
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.37
Upside: +89.87%
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $1.72
Upside: +5,730.90%